Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
PaperCitations, authors & open-access status
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 578 citations, 2019 year and gold oa status.
578
Citations
2019
Year
gold
OA Status